Episodes

  • You’ve Had Back Pain for 7-10 Years? Neil Klompas, CEO, Augurex

    You’ve Had Back Pain for 7-10 Years? Neil Klompas, CEO, Augurex
    Jan 27 2026

    This is the 2026 BioTech Nation "5":
    Five Companies Ready to Make a Difference.
    We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
    Hear all 5 interviews at     https://www.biotechnation.com/jpm-2026-btn-5


    On this episode of BioTech Nation...Moira speaks with Neil Klompas of Augurex Life Sciences, about a new diagnostic for chronic, long-term back pain that pinpoints a form of arthritis. On average, patients with this condition could go 7-10 years without a diagnosis, having to first eliminate everything else with an odyssey of tests. Now, a simple blood test could be the answer.

    For more information about BioTech Nation and the companies featured here, visit: TechNation.com
    Show More Show Less
    9 mins
  • A Fast-Acting Dupixent? Dr. Barry Quart, CEO, Connect Biopharma

    A Fast-Acting Dupixent? Dr. Barry Quart, CEO, Connect Biopharma
    Jan 11 2026

    This is the 2026 BioTech Nation "5":
    Five Companies Ready to Make a Difference.
    We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
    Hear all 5 interviews at     https://www.biotechnation.com/jpm-2026-btn-5


    On this episode of BioTech Nation, Moira speaks with Dr. Barry Quart, CEO of Connect Biopharma, about a new fast-acting treatment for inflammatory conditions like Asthma, COPD, and Eczema. Often, these conditions can be managed with anti-inflammatory therapeutics like Dupixent, but even then, sudden and painful flare-ups can occur. We take a closer look at a new anti-inflammatory in late-stage development which starts working quickly, much needed when those flare-ups develop.

    For more information about BioTech Nation and the companies featured here, visit: TechNation.com
    Show More Show Less
    11 mins
  • A Speedy Intervention for Heart Attacks, Dr. Harry Selker & Dr. Atul Deshpande, Immediate Therapeutics

    A Speedy Intervention for Heart Attacks, Dr. Harry Selker & Dr. Atul Deshpande, Immediate Therapeutics
    Jan 13 2026

    This is the 2026 BioTech Nation "5":
    Five Companies Ready to Make a Difference.
    We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
    Hear all 5 interviews at     https://www.biotechnation.com/jpm-2026-btn-5


    On this episode of BioTech Nation...
    Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.

    For more information about BioTech Nation and the companies featured here, visit: TechNation.com
    Show More Show Less
    21 mins
  • A Euphoria-Suppressing Opioid, Ketan Mehta, Founder & CEO, Tris Pharma

    A Euphoria-Suppressing Opioid, Ketan Mehta, Founder & CEO, Tris Pharma
    Jan 11 2026

    This is the 2026 BioTech Nation "5":
    Five Companies Ready to Make a Difference.
    We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
    Hear all 5 interviews at     https://www.biotechnation.com/jpm-2026-btn-5


    On this episode of BioTech Nation...
    Ever wonder what makes opioids so addictive? Moira speaks with Ketan Mehta, Founder and CEO of Tris Pharma, about opioid-induced euphoria...and an opioid that's actually meant to suppress this response.

    For more information about BioTech Nation and the companies featured here, visit: TechNation.com
    Show More Show Less
    16 mins
  • A New Way to Treat Cancer, Cyriac Roeding & Dr. David Suhy, Co-Founders, Earli

    A New Way to Treat Cancer, Cyriac Roeding & Dr. David Suhy, Co-Founders, Earli
    Jan 6 2026

    This is the 2026 BioTech Nation "5":
    Five Companies Ready to Make a Difference.
    We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco.
    Hear all 5 interviews at     https://www.biotechnation.com/jpm-2026-btn-5


    On this episode of BioTech Nation: Can cancer cells be turned against themselves? Moira speaks with Cyriac Roeding and Dr. David Suhy, Co-Founders of Earli, about an innovative new approach to treating solid tumor cancer. They discuss their effort to turn the cancer cells inside solid tumors into factories that produce their own cancer-fighting therapeutic.

    For more information about BioTech Nation and the companies featured here, visit: TechNation.com
    Show More Show Less
    24 mins
  • Decoding Diseases of Aging...Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology

    Decoding Diseases of Aging...Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian Biotechnology
    Dec 31 2025

    This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.
    Show More Show Less
    26 mins
  • When Your Immune System Overreacts...Prof. Dr. Niels Riedemann, Co-Founder & CEO, InflaRx

    When Your Immune System Overreacts...Prof. Dr. Niels Riedemann, Co-Founder & CEO, InflaRx
    Dec 23 2025

    This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies.

    Show More Show Less
    22 mins
  • Renewed Potential: Reviving an ALS Drug...Dr. Ari Azhir, Founder & CEO, Neuvivo

    Renewed Potential: Reviving an ALS Drug...Dr. Ari Azhir, Founder & CEO, Neuvivo
    Dec 17 2025

    This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.
    Show More Show Less
    18 mins